This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Monk, J. P. Articles by Villalona-Calero, M. A. Search for Related Content PubMed PubMed Citation Articles by Monk, J. P. Articles by Villalona-Calero, M. A. Social Bookmarking                            What's this?

Assessment of Tumor Necrosis Factor Alpha Blockade As an Intervention to Improve Tolerability of Dose-Intensive Chemotherapy in Cancer Patients

J. Paul Monk, Gary Phillips, Ross Waite, John Kuhn, Larry J. Schaaf, Gregory A. Otterson, Denis Guttridge, Chris Rhoades, Manisha Shah, Tamara Criswell, Michael A. Caligiuri, Miguel A. Villalona-Calero

From the Division of Hematology/Oncology, Department of Internal Medicine and Center for Biostatistics, The Ohio State University College of Medicine and Public Health; The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital & Richard J. Solove Research Institute, Ohio State University, Columbus, OH; and The University of Texas Health Science Center at San Antonio, San Antonio, TX

Address reprint requests to Miguel A. Villalona-Calero, MD, The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital, Ohio State University, B406 Starling-Loving Hall, 320 W 10th Ave, Columbus, OH 43210-1240; e-mail: MigueL.Villalona{at}osumc.edu

PURPOSE: Maintaining dose-intensity with chemotherapeutic agents is hindered by a number of adverse effects including asthenia/fatigue. Tumor necrosis factor (TNF) is one of the cytokines responsible for the fatigue and cachexia associated with malignancies. We used etanercept (TNF-decoy receptor) to maintain dose-intensity of weekly docetaxel.

PATIENTS AND METHODS: Initially, 12 patients with advanced malignancies were randomly assigned to either docetaxel 43 mg/m² weekly alone (cohort A) or the same docetaxel dose plus etanercept 25 mg subcutaneously twice weekly (cohort B). Subsequently, higher doses of docetaxel in combination with etanercept were evaluated. Pharmacokinetics (PKs), nuclear factor-kappa B (NF-B) activation, and intracellular cytokines levels were measured. Patients completed weekly questionnaires quantifying asthenia/fatigue.

RESULTS: Twenty-nine of 36 intended docetaxel doses during the first cycle were delivered in cohort A, and 35 of 36 doses were delivered in cohort B (P = .055). Three cohort B patients received additional cycles in the absence of disease progression or severe toxicity, whereas no patients from cohort A received additional cycles. Escalation to docetaxel 52 mg/m² weekly with etanercept resulted in neutropenia, not fatigue, as the limiting adverse effect, and the addition of filgrastim permitted the maintenance of dose-intensity in additional patients. Patients randomly selected to receive etanercept/docetaxel self-reported less fatigue (P < .001), and docetaxel PKs show no relevant influence of etanercept. NF-B activation and increased expression of TNF- were associated with increments in docetaxel dose. Antitumor activity was noticed exclusively in patients receiving etanercept.

CONCLUSION: The addition of etanercept is safe and had no impact on docetaxel concentrations. The significant improvement in tolerability and the trend toward preservation of dose-intensity suggests further exploration of TNF blockade as an adjunct to cancer therapies.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. E. Bower, P. A. Ganz, M. L. Tao, W. Hu, T. R. Belin, S. Sepah, S. Cole, and N. Aziz Inflammatory Biomarkers and Fatigue during Radiation Therapy for Breast and Prostate Cancer Clin. Cancer Res., September 1, 2009; 15(17): 5534 - 5540. [Abstract] [Full Text] [PDF]

				D. Surguladze, D. Deevi, N. Claros, E. Corcoran, S. Wang, M. J. Plym, Y. Wu, J. Doody, D. J. Mauro, L. Witte, et al. Tumor Necrosis Factor-{alpha} and Interleukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice Cancer Res., July 15, 2009; 69(14): 5643 - 5647. [Abstract] [Full Text] [PDF]

				Z. Wang, C. Zhao, R. Moya, and J. D. Davies A Novel Role for CD4+ T Cells in the Control of Cachexia J. Immunol., October 1, 2008; 181(7): 4676 - 4684. [Abstract] [Full Text] [PDF]

				O. Minton, A. Richardson, M. Sharpe, M. Hotopf, and P. Stone A Systematic Review and Meta-Analysis of the Pharmacological Treatment of Cancer-Related Fatigue J Natl Cancer Inst, August 20, 2008; 100(16): 1155 - 1166. [Abstract] [Full Text] [PDF]

				A. H. Miller, S. Ancoli-Israel, J. E. Bower, L. Capuron, and M. R. Irwin Neuroendocrine-Immune Mechanisms of Behavioral Comorbidities in Patients With Cancer J. Clin. Oncol., February 20, 2008; 26(6): 971 - 982. [Abstract] [Full Text] [PDF]

				J. E. Bower Behavioral Symptoms in Patients With Breast Cancer and Survivors J. Clin. Oncol., February 10, 2008; 26(5): 768 - 777. [Abstract] [Full Text] [PDF]